A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

Start Date22 Apr 2024

Sponsor / Collaborator

Famy Life Sciences Pvt Ltd.

CTRI/2024/03/063709 / RecruitingNot Applicable

A Randomized, Double Blind, Placebo Controlled, Three arm, Parallel, Multicentre, Study to Evaluate the Bioequivalence using Clinical Endpoint of Pimecrolimus Cream, 1% of Encube Ethicals Private Limited, India to Pimecrolimus Cream, 1% of Oceanside Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA in Treatment of Mild to Moderate Atopic Dermatitis. - Nil

Start Date15 Mar 2024

Sponsor / Collaborator

Encube Ethicals Pvt Ltd.

NCT06241118 / RecruitingPhase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy.
The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy.
Study details include:
At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD).
The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up.
The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period.
The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).

Start Date29 Feb 2024

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Pimecrolimus

100 Translational Medicine associated with Pimecrolimus

100 Patents (Medical) associated with Pimecrolimus

874

Literatures (Medical) associated with Pimecrolimus

28 Jun 2024·Cureus

Resolution of Discoid Lupus Alopecia With Systemic Hydroxychloroquine and Topical Pimecrolimus Combination Therapy

Article

Author: Hilts, Alexis ; Liang, Kristine R ; Lee, Cynthia ; Greenberg, H L

Discoid lupus erythematosus (DLE) is an autoimmune skin condition that is typically part of the cutaneous manifestation of systemic lupus erythematosus (SLE). DLE is characterized by erythematous patches that can progress to depigmentation and alopecia, leading to scarring and permanent hair loss if left untreated. Herein, we present a unique case of localized DLE on the scalp in a 46-year-old female with no prior history of autoimmune disorders. The patient underwent several medication trials, including intralesional corticosteroids, topical calcineurin inhibitors, topical corticosteroids, and systemic hydroxychloroquine, with limited success in treating her discoid alopecia. Subsequently, a combination therapy of oral hydroxychloroquine and topical pimecrolimus significantly improved her scalp lesion. This case highlights the efficacy of combination therapy in managing localized DLE, providing valuable insights for future research focused on DLE alopecia management and optimizing treatment strategies for similar cases.

06 May 2024·Journal of Burn Care & Research

Nonsurgical Treatment of Postburn Hypopigmentation: A Literature Review

Review

Author: Berkane, Yanis ; Bertheuil, Nicolas ; Vaillant, Camille ; Lupon, Elise ; Chaput, Benoît ; Lellouch, Alexandre G ; Camuzard, Olivier ; Cetrulo, Curtis L

AbstractThe treatment of postburn hypopigmentation was primarily surgical before the advent of new technologies. Medical devices and therapies are emerging to manage scar sequelae that can be disfiguring and associated with severe psychosocial impact. These innovations have been poorly investigated for hypopigmentation, but they represent a real hope. We reviewed all articles published on Pubmed up to June 2022. Included studies had to specifically focus on treating postburn hypopigmented scars. All articles evaluating transient solutions such as make-up, and articles describing inflammation-linked hypopigmentation with no etiological details or no burn injury history were excluded. Through this review, we have highlighted 6 different types of nonsurgical treatments reported in postburn leukoderma potentially allowing definitive results. Electrophoto-biomodulation or E light (combining intensive pulsed light, radiofrequency, and cooling), topical daylight psoralen UVA therapy, and lasers (fractional lasers using pulse energies or CO2FL devices, lasers-assisted drug delivery as local bimatoprost and tretinoin or pimecrolimus) have been explored with encouraging results in hypopigmented burns. Finally, other promising medical strategies include using FK506, a nonsteroidal anti-inflammatory drug, to induce melanogenesis or using melanocyte-stimulating hormones with fractional laser-assisted drug deliveries, which are expected to emerge soon.

02 Apr 2024·Expert Opinion on Drug Metabolism & Toxicology

Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients

Review

Author: Feldman, Steven R. ; Lo, Angela ; Chodri, Kamran ; Gantz, Hannah Y. ; Greenzaid, Jonathan D.

INTRODUCTIONPsoriasis is a chronic inflammatory cutaneous disease that causes patients psychosocial distress. Topical therapies are utilized for mild-to-moderate disease and for more severe disease in conjunction with systemic therapies. Topical corticosteroids are a cornerstone of treatment for psoriasis, but long-term use can cause stria and cutaneous atrophy and as well as systemic side effects such as topical steroid withdrawal. Non-steroidal topical therapies tend to be safer than topical corticosteroids for long-term use.AREAS COVEREDWe conducted a literature review on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of topical therapies for psoriasis. We discuss how the PK and PD characteristics of these therapies inform clinicians on efficacy and toxicity when prescribing for patients.EXPERT OPINIONTopical corticosteroids, used intermittently, are very safe and effective. Long-term, continuous use of topical corticosteroids can cause systemic side effects. Several generic and newly approved non-steroidal options are available, but no head-to-head studies compare the effectiveness of the generics (vitamin D analogs, tacrolimus, pimecrolimus) against the newer therapies (roflumilast, tapinarof). Patients often do not respond to topical therapies due to poor adherence to treatment regimens. For patients resistant to topical treatment, phototherapy or systemic therapy may be an option.

News (Medical) associated with Pimecrolimus

12 Jan 2023

·www.prnewswire.com

AMERICAN ACADEMY OF DERMATOLOGY ISSUES UPDATED GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS IN ADULTS WITH TOPICAL THERAPIES

Both well-established and newer topical treatments addressed ROSEMONT, Ill., Jan. 12, 2023 /PRNewswire/ -- Often called eczema or atopic eczema, atopic dermatitis is a common skin condition, affecting 1 in 10 Americans1. Although atopic dermatitis occurs most frequently in children, it also affects adults and can have a significant impact on patients' quality of life. To help ensure that adult patients with atopic dermatitis receive the best possible treatment, the American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy of Dermatology. Continue Reading This is the second in a series of updated guidelines the AAD is producing on the condition. The updates, which outline best practices for topical treatment of the disease, were developed by an expert workgroup of 12 physicians, including 11 dermatologists, an allergist/pediatrician and one patient representative. The AAD published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies Tweet this "Atopic dermatitis is the most common type of eczema, and it can interfere with a person's daily life without proper treatment," said board-certified dermatologist Robert Sidbury, MD, MPH, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "The guidelines provide evidence-based recommendations for dermatologists to use in caring for their adult atopic dermatitis patients with topical treatments, which have come a long way since the guidelines were last revised in 2014. This update reflects the latest advances in topical medications that are now available to help adults with atopic dermatitis." Atopic dermatitis can develop on any area of your skin at any age. Adults who have atopic dermatitis often have red to dark patches and scaly skin. They also can have extremely dry skin, hand eczema, eye problems, and skin that is easily irritated. "While atopic dermatitis cannot be cured, it can be controlled with proper treatment," said Dr. Sidbury. "A plan created by a board-certified dermatologist can help ease symptoms, reduce flare-ups, and prevent it from worsening. Topical treatments remain one of the most popular options due to their effective track record and overall safety." The Atopic Dermatitis Workgroup developed 12 recommendations on how to manage atopic dermatitis in adults with topical therapies. The workgroup provided new recommendations for non-prescription methods as well as prescription treatments. Strong recommendations were made for topical treatments in which the benefits clearly outweigh the risks and burdens to the patient. These recommendations apply to most patients in most circumstances. Strong recommendations were made for the use of the following: Moisturizers help to relieve patients' dry, cracked skin, decrease inflammation, and reduce the severity of and increase the time between flare-ups. Topical calcineurin inhibitors (pimecrolimus 1% cream and tacrolimus 0.03% or 0.1% ointment) reduce patients' inflammation and itching, as well as decrease their flare-ups. Topical corticosteroids are commonly used as the first-line treatment for patients with atopic dermatitis in all skin regions. They help to relieve itching, decrease inflammation, and can decrease infections. Phosphodiesterase-4 inhibitor (crisaborole ointment) can reduce patients' inflammation, help relieve itching, and decrease infections. Janus kinase inhibitor (ruxolitinib cream) can be used short term to ease the inflammation and itching of patients with mild to moderate atopic dermatitis. The guidelines provide conditional recommendations for the use of bathing and wet wrap therapy. Conditional recommendations apply to most patients, but the most appropriate action may differ depending on individual patient factors. Bathing, followed by moisturization , helps patients hydrate the skin. Bleach baths can help patients prevent infection and get rid of bacteria on their skin. Wet wrap therapy utilizes wet bandages to help hydrate and soothe patients' skin. This treatment provides a barrier against scratching, helps to decrease redness and inflammation, and can reduce the bacteria on patients' skin. "These recommendations are based on the latest evidence-based research on the most effective topical treatments for our patients," said Dawn Davis, MD, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "These recommended treatments can be used individually or in combination with other treatments." The guidelines made conditional recommendations against the use of topical antimicrobials, antiseptics, and antihistamines due to the low certainty of evidence, which means the true effect may be substantially different from the estimated effect. "These guidelines were updated to enable dermatologists to optimize topical treatments to provide adult atopic dermatitis patients with expert care," said board-certified dermatologist Mark D. Kaufmann MD, FAAD, president of the AAD. "Since each patient's atopic dermatitis is unique, board-certified dermatologists can determine the treatments that will work best for them. I'm very grateful to our workgroup for providing these important updates to help patients worldwide." To find a board-certified dermatologist in your area, visit aad.org/findaderm. More information: Eczema Types: Atopic Dermatitis Overview Eczema Types: Atopic Dermatitis Symptoms Guidelines of care for the management of atopic dermatitis in adults with topical therapies About the AAD 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest and YouTube and @AADskin1 on Instagram. About JAAD The Journal of the American Academy of Dermatology is the most widely read dermatology journal in the world, according to Kantar Media. JAAD was the first most-cited dermatology journal in 2021, according to impact factor rankings from Clarivate's Journal Citation Reports (JCR) Web of Science Group. JAAD also has two open-access companion titles: JAAD Case Reports and JAAD International. Follow @JAADJournals on Facebook, Twitter, and Instagram. SOURCE American Academy of Dermatology

12 Jan 2023

·www.biospace.com

American Academy of Dermatology Issues Updated Guidelines for the Management of Atopic Dermatitis in Adults With Topical Therapies

Both well-established and newer topical treatments addressed ROSEMONT, Ill., Jan. 12, 2023 /PRNewswire/ -- Often called eczema or atopic eczema, atopic dermatitis is a common skin condition, affecting 1 in 10 Americans1. Although atopic dermatitis occurs most frequently in children, it also affects adults and can have a significant impact on patients' quality of life. To help ensure that adult patients with atopic dermatitis receive the best possible treatment, the American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy of Dermatology. The AAD published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies This is the second in a series of updated guidelines the AAD is producing on the condition. The updates, which outline best practices for topical treatment of the disease, were developed by an expert workgroup of 12 physicians, including 11 dermatologists, an allergist/pediatrician and one patient representative. "Atopic dermatitis is the most common type of eczema, and it can interfere with a person's daily life without proper treatment," said board-certified dermatologist Robert Sidbury, MD, MPH, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "The guidelines provide evidence-based recommendations for dermatologists to use in caring for their adult atopic dermatitis patients with topical treatments, which have come a long way since the guidelines were last revised in 2014. This update reflects the latest advances in topical medications that are now available to help adults with atopic dermatitis." Atopic dermatitis can develop on any area of your skin at any age. Adults who have atopic dermatitis often have red to dark patches and scaly skin. They also can have extremely dry skin, hand eczema, eye problems, and skin that is easily irritated. "While atopic dermatitis cannot be cured, it can be controlled with proper treatment," said Dr. Sidbury. "A plan created by a board-certified dermatologist can help ease symptoms, reduce flare-ups, and prevent it from worsening. Topical treatments remain one of the most popular options due to their effective track record and overall safety." The Atopic Dermatitis Workgroup developed 12 recommendations on how to manage atopic dermatitis in adults with topical therapies. The workgroup provided new recommendations for non-prescription methods as well as prescription treatments. Strong recommendations were made for topical treatments in which the benefits clearly outweigh the risks and burdens to the patient. These recommendations apply to most patients in most circumstances. Strong recommendations were made for the use of the following: Moisturizers help to relieve patients' dry, cracked skin, decrease inflammation, and reduce the severity of and increase the time between flare-ups. Topical calcineurin inhibitors (pimecrolimus 1% cream and tacrolimus 0.03% or 0.1% ointment) reduce patients' inflammation and itching, as well as decrease their flare-ups. Topical corticosteroids are commonly used as the first-line treatment for patients with atopic dermatitis in all skin regions. They help to relieve itching, decrease inflammation, and can decrease infections. Phosphodiesterase-4 inhibitor (crisaborole ointment) can reduce patients' inflammation, help relieve itching, and decrease infections. Janus kinase inhibitor (ruxolitinib cream) can be used short term to ease the inflammation and itching of patients with mild to moderate atopic dermatitis. The guidelines provide conditional recommendations for the use of bathing and wet wrap therapy. Conditional recommendations apply to most patients, but the most appropriate action may differ depending on individual patient factors. Bathing, followed by moisturization, helps patients hydrate the skin. Bleach baths can help patients prevent infection and get rid of bacteria on their skin. Wet wrap therapy utilizes wet bandages to help hydrate and soothe patients' skin. This treatment provides a barrier against scratching, helps to decrease redness and inflammation, and can reduce the bacteria on patients' skin. "These recommendations are based on the latest evidence-based research on the most effective topical treatments for our patients," said Dawn Davis, MD, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "These recommended treatments can be used individually or in combination with other treatments." The guidelines made conditional recommendations against the use of topical antimicrobials, antiseptics, and antihistamines due to the low certainty of evidence, which means the true effect may be substantially different from the estimated effect. "These guidelines were updated to enable dermatologists to optimize topical treatments to provide adult atopic dermatitis patients with expert care," said board-certified dermatologist Mark D. Kaufmann MD, FAAD, president of the AAD. "Since each patient's atopic dermatitis is unique, board-certified dermatologists can determine the treatments that will work best for them. I'm very grateful to our workgroup for providing these important updates to help patients worldwide." To find a board-certified dermatologist in your area, visit aad.org/findaderm. More information: Eczema Types: Atopic Dermatitis Overview Eczema Types: Atopic Dermatitis Symptoms Guidelines of care for the management of atopic dermatitis in adults with topical therapies About the AAD 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest and YouTube and @AADskin1 on Instagram. About JAAD The Journal of the American Academy of Dermatology is the most widely read dermatology journal in the world, according to Kantar Media. JAAD was the first most-cited dermatology journal in 2021, according to impact factor rankings from Clarivate's Journal Citation Reports (JCR) Web of Science Group. JAAD also has two open-access companion titles: JAAD Case Reports and JAAD International. Follow @JAADJournals on Facebook, Twitter, and Instagram. View original content: SOURCE American Academy of Dermatology

08 Nov 2022

·medcitynews.com

Viatris Sees Vision Drugs as Key to Growth and Commits $750M to Two M&A Deals

Viatris, which is in the midst of a strategy shift intended to return the company to revenue growth, is acquiring two companies that together bring one commercialized product and five programs ready for pivotal testing or already in Phase 3 development. The new assets coming to Viatris are in ophthalmology, one of the new areas of focus for the company. In total, Viatris said it expects to spend between $700 million and $750 million to acquire publicly traded Oyster Point Pharma and privately held Famy Life Sciences. The acquisitions announced Monday come less than two years after the close of the merger that formed Viatris, bringing together the generic drugs giant Mylan with Upjohn, the generic medications and off-patent drugs unit of Pfizer. In its new incarnation, Viatris aimed to offer a portfolio of drugs projected to top $3 billion in global revenue. The Canonsburg, Pennsylvania-based company would soon change course. In February, Viatris announced it had agreed to sell its biosimilars business to Biocon Biologics for $3.3 billion. That deal resulted from a strategic review conducted to streamline the business and better position it for growth. “Non-core” assets like biosimilars would be sold. The remaining Viatris business would focus on three therapeutic areas: ophthalmology, gastrointestinal, and dermatology. At the time that deal was announced, Viatris also disclosed it had acquired rights to Pimecrolimus, an eye ointment to treat blepharitis, a type of eye irritation. The company’s latest deals further expand its eye drug ambitions. Oyster Point’s main asset is Tyrvaya, a dry eye disease drug approved last year that the biotech company developed in a nasal spray formulation. The drug works by binding to certain receptors, activating them to stimulate cells and glands involved in producing the tear film covering the eye. For the first half of this year, the Princeton, New Jersey-based company reported the drug accounted for $7.3 million in revenue. Oyster Point’s pipeline includes two preclinical gene therapies in development for certain eye surface diseases. According to the financial terms of deal, Viatris will pay $11 cash for each share of Oyster Point. That price is a 31.7% premium to the stock’s closing price last Friday. The agreement also includes a contingent value right, an additional $2 per share payment that’s tied to Oyster Point achieving certain goals. Viatris is paying about $300 million to acquire Famy Life Sciences, according to the Economic Times, a business newspaper in India, where Famy is based. The Times reported that the Taparia family, which owned the company, will keep retain the non-ophthalmic business. There’s history behind the transaction. In 2015, Mylan paid $750 million up front to acquire Famy Care, a women’s healthcare company started by the Taparias. Family members started Famy Life Sciences in 2017. According to a Viatris investor presentation, Famy’s five clinical-stage ophthalmic programs include Phase 3-ready assets for dry eye disease, blepharitis, and presbyopia. A drug candidate for dim light or night vision disturbances is already in Phase 3 testing; a Phase 3 test in rehydration of mydriasis is complete. The products and product candidates coming to the company in the acquisitions are projected to generate more than $1 billion in revenue by 2028, Viatris said in the presentation. “These acquisitions bring us an innovative growth asset, Tyrvaya, and five additional Phase 3 or Phase 3-ready programs that give us a significant head-start in creating a leading ophthalmology franchise,” Viatris CEO Michael Goettler said in a prepared statement. The Oyster Point acquisition is expected to close in the first quarter of 2023. When it does, Oyster Point CEO Jeff Nau will lead the new Viatris ophthalmology business, which will operate as a separate division within the larger company.

Generic DrugBiosimilarAcquisition

100 Deals associated with Pimecrolimus

External Link

KEGG	Wiki	ATC	Drug Bank
D05480	Pimecrolimus	D11AH02	DB00337

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eczema	CN	Novartis Pharma AG	29 Sep 2005
Dermatitis, Atopic	US	Bausch Health US LLC	13 Dec 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Blepharitis	Phase 3	US	Famy Life Sciences Pvt Ltd.	22 Apr 2024
Dermatitis, Perioral	Phase 3	DE	Novartis AG	01 Sep 2005
Chronic dermatitis	Phase 3	-	Novartis AG	01 Jul 2004
Dermatitis, Atopic	Phase 3	JP	Novartis AG	01 May 2004
Vitiligo	Phase 3	BE	Novartis AG	01 May 2004
Mild Atopic Dermatitis	Phase 3	DE	MEDA Pharma GmbH & Co. KG	01 Apr 2004
Mild Atopic Dermatitis	Phase 3	US	MEDA Pharma GmbH & Co. KG	01 Apr 2004
Moderate Atopic Dermatitis	Phase 3	US	MEDA Pharma GmbH & Co. KG	01 Apr 2004
Moderate Atopic Dermatitis	Phase 3	DE	MEDA Pharma GmbH & Co. KG	01 Apr 2004
Severe Atopic Dermatitis	Phase 3	DE	Novartis AG	01 Dec 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Not Applicable	Dermatitis, Atopic	-	Pimecrolimus	rtvdfnkwwm(ofdhxkqjmm) = for at least three months kfsncwrkyj (anddhhbqgv )	Positive	03 Jul 2023
NCT00120523 (PETITE study, EADV2022)	Phase 3	Dermatitis, Atopic	120	Pimecrolimus 1% cream	(keymoleqvd) = The most frequently reported AEs (≥ 30% in any treatment group) are listed in Table-1. These AEs were reported by similar proportions of patients treated with PIM or TCS. iivdhupctu (soxnzwnsbq )	-	07 Sep 2022
				Topical corticosteroids (TCS)
NCT00403559 (CTgov)	Phase 2	Dermatitis, Seborrheic	113	Elidel (Elidel Cream (Pimecrolimus))	piljngddhl(tkurkwejkh) = pibtsllosi ghcsbelsix (nfvdrvdzdv, qyoaihymdn - rgjqzjpaxg)	-	14 Mar 2022
				Ketoconazole Cream (Ketoconazole Cream (Nizoral))	piljngddhl(tkurkwejkh) = dtlxmpjmzi ghcsbelsix (nfvdrvdzdv, ehdpqqbfpx - qjtvlewvzq)
NCT02791308 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Mild Atopic Dermatitis	587	Pimecrolimus Cream, 1% (Pimecrolimus Cream, 1%)	ctnwhwlazo(utpwqcxcgr) = thxfpugjkt clzcgiypnj (inlglfugwz, vkhfuarqkn - qbkawkfber) View more	-	24 Apr 2020
				Pimecrolimus Cream 1% (Valeant) (Elidel Cream, 1%)	ctnwhwlazo(utpwqcxcgr) = kkpkpizsug clzcgiypnj (inlglfugwz, aehllbqjlc - fkxzxpiwmx) View more
NCT03107611 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Mild Atopic Dermatitis	654	Pimecrolimus Cream, 1% (Test)	fatnimyntu(mumpzcbzjh) = poovasftis dsiniymyru (crtskfwsog, txpvprnhwz - fmmiwvlbvo) View more	-	17 Mar 2020
				Pimecrolimus Cream, 1% (Reference Standard)	fatnimyntu(mumpzcbzjh) = dgburrkmhs dsiniymyru (crtskfwsog, zxvcknkzkk - nuqparqvlz) View more
NCT01692626 (CTgov)	Phase 2	Exanthema	13	sidePimecrolimus (Left sidePimecrolimus Cream)	yjdddwgfye(hlveaovdab) = zlbdrxgxsf iqvfikgkfh (olaobkpvfp, ojzjzeksfc - exfujncfzq)	-	15 Mar 2017
				Pimecrolimus Cream (The Right Side the Pimecrolimus Cream)	yjdddwgfye(hlveaovdab) = wbacquqgaf iqvfikgkfh (olaobkpvfp, ybaxcetmrj - negzveiqgq)
NCT00120523 (Pubmed \| Pediatrics) Manual	Phase 3	Dermatitis, Atopic First line	2,418	pimecrolimus	(lvbintdlku) = pburjcrxzw ljuvqpvkpz (rolromjsrm ) View more	Similar	01 Apr 2015
				topical corticosteroids	(lvbintdlku) = fhdqzlgwxn ljuvqpvkpz (rolromjsrm ) View more
NCT00208026 (CTgov)	Phase 1/2	Netherton Syndrome	3	Pimecrolimus Cream (Patient 1)	zwkiqqjaty(xzupnnzrge) = lzqjpdgvns ipcyutsjsf (jzwmxvowrh, yhsbsgpclh - hpayabdmez) View more	-	12 Dec 2014
				Pimecrolimus Cream (Patient 2)	zwkiqqjaty(xzupnnzrge) = dnaovmpopk ipcyutsjsf (jzwmxvowrh, kdpecbuhid - wmuxlepxlm) View more
NCT00946478 (CTgov)	Not Applicable	Eczema \| Dermatitis, Atopic	40	Pimecrolimus (Pimecrolimus)	cyvgtqcoxc(yrheayjipp) = imzprkidrm bdgkyknggl (bcuxizpevb, ogkfswfmov - ubsgcnrmoa) View more	-	10 Mar 2014
				Vehicle cream (Vehicle Cream)	cyvgtqcoxc(yrheayjipp) = obthbsffxa bdgkyknggl (bcuxizpevb, oxtrzxpobw - szzppuojmt) View more
NCT00120523 (PETITE study, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Mild Atopic Dermatitis	2,418	Pimecrolimus (Pimecrolimus)	effvjrcrvj(hfhegwriag) = htjtyencna ygarhdceaj (nnktzpgnmk, wgockicchi - mizqaxcity) View more	-	16 Jan 2013
				Corticosteroids (Topical Corticosteroids)	effvjrcrvj(hfhegwriag) = guaneicert ygarhdceaj (nnktzpgnmk, kliqqgpfvd - lignvdkufp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis